Queen Saovabha Memorial Institute
12
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
33%
2 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response
Role: lead
Immunological Tolerance After Frequent Rabies Booster Vaccinations
Role: lead
Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults
Role: lead
Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults
Role: lead
Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response
Role: lead
Two-site Intradermal Influenza Vaccination in Elderly
Role: lead
Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins
Role: lead
Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG
Role: lead
Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
Role: lead
Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children
Role: lead
Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV
Role: lead
Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
Role: lead
All 12 trials loaded